Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12299749 | 1.00 | ELANE (0.51) | ELANENPC1RAB9ASMN1; SMN2CCR5 | |
| SCHEMBL10169570 | 0.96 | PREP (0.53) | — | |
| SCHEMBL929468 | 0.95 | AGTR2 (0.49) | ELANECCR5 | |
| SCHEMBL18477527 | 0.95 | FKBP1A (0.52) | — | |
| SCHEMBL30315726 | 0.95 | PDK1 (0.51) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30315793 | 0.95 | PDK1 (0.51) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10170415 | 0.91 | ELANE (0.50) | ELANE | |
| SCHEMBL31727301 | 0.88 | SMN1; SMN2 (0.56) | NPC1RAB9ASMN1; SMN2CCR5 | |
| SCHEMBL31727280 | 0.88 | SMN1; SMN2 (0.56) | NPC1RAB9ASMN1; SMN2CCR5 | |
| SCHEMBL2632237 | 0.87 | ELANE (0.49) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | ELANE 692/4885NPC1 757/4885RAB9A 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.